199 related articles for article (PubMed ID: 27196445)
1. γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.
Görtzen J; Hunka LM; Vonnahme M; Praktiknjo M; Kaifie A; Fimmers R; Jansen C; Heine A; Lehmann J; Goethert JR; Gattermann N; Goekkurt E; Platzbecker U; Brossart P; Strassburg CP; Brummendorf TH; Koschmieder S; Wolf D; Trebicka J
Medicine (Baltimore); 2016 May; 95(20):e3355. PubMed ID: 27196445
[TBL] [Abstract][Full Text] [Related]
2. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
[TBL] [Abstract][Full Text] [Related]
3. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
4. Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.
Beleva EA
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958701
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses.
Debureaux PE; Cassinat B; Soret-Dulphy J; Mora B; Verger E; Maslah N; Plessier A; Rautou PE; Ollivier-Hourman I; De Ledinghen V; Goria O; Bureau C; Siracusa C; Valla D; Giraudier S; Passamonti F; Kiladjian JJ
Blood Adv; 2020 Aug; 4(15):3708-3715. PubMed ID: 32777065
[TBL] [Abstract][Full Text] [Related]
7. Splanchnic vein thrombosis in myeloproliferative neoplasms.
Sekhar M; McVinnie K; Burroughs AK
Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
[TBL] [Abstract][Full Text] [Related]
8. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.
Sant'Antonio E; Guglielmelli P; Pieri L; Primignani M; Randi ML; Santarossa C; Rumi E; Cervantes F; Delaini F; Carobbio A; Betti S; Rossi E; Lavi N; Harrison CN; Curto-Garcia N; Gisslinger H; Gisslinger B; Specchia G; Ricco A; Vianelli N; Polverelli N; Koren-Michowitz M; Ruggeri M; Girodon F; Ellis M; Iurlo A; Mannelli F; Mannelli L; Sordi B; Loscocco GG; Cazzola M; De Stefano V; Barbui T; Tefferi A; Vannucchi AM
Am J Hematol; 2020 Feb; 95(2):156-166. PubMed ID: 31721282
[TBL] [Abstract][Full Text] [Related]
9. Splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Tremblay D; Winters A; Beckman JD; Naymagon L; Patel R; Mascarenhas J; Schiano TD
Thromb Res; 2022 Oct; 218():8-16. PubMed ID: 35963121
[TBL] [Abstract][Full Text] [Related]
10. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
11. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
Garrote M; López-Guerra M; García-Pagán JC; Arellano-Rodrigo E; Ferrer-Marín F; Hernández-Boluda JC; Bellosillo B; Nomdedeu M; Hernández-Gea V; Triguero A; Guijarro F; Álamo J; Baiges A; Turon F; Colomer D; Cervantes F; Alvarez-Larrán A
Ann Hematol; 2024 Mar; 103(3):737-747. PubMed ID: 38263537
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Pieri L; Paoli C; Arena U; Marra F; Mori F; Zucchini M; Colagrande S; Castellani A; Masciulli A; Rosti V; De Stefano V; Betti S; Finazzi G; Ferrari ML; Rumi E; Ruggeri M; Nichele I; Guglielmelli P; Fjerza R; Mannarelli C; Fanelli T; Merli L; Corbizi Fattori G; Massa M; Cimino G; Rambaldi A; Barosi G; Cazzola M; Barbui T; Vannucchi AM
Am J Hematol; 2017 Feb; 92(2):187-195. PubMed ID: 27880982
[TBL] [Abstract][Full Text] [Related]
13. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
14. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
[TBL] [Abstract][Full Text] [Related]
15. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
16. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
17. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
18. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
How J; Zhou A; Oh ST
Ther Adv Hematol; 2017 Mar; 8(3):107-118. PubMed ID: 28246554
[TBL] [Abstract][Full Text] [Related]
19. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
Finazzi G; De Stefano V; Barbui T
Blood Cancer J; 2018 Jun; 8(7):64. PubMed ID: 29946154
[TBL] [Abstract][Full Text] [Related]
20. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
Kaifie A; Kirschner M; Wolf D; Maintz C; Hänel M; Gattermann N; Gökkurt E; Platzbecker U; Hollburg W; Göthert JR; Parmentier S; Lang F; Hansen R; Isfort S; Schmitt K; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
J Hematol Oncol; 2016 Mar; 9():18. PubMed ID: 26944254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
